Skip to main content

Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial.

Publication ,  Conference
Thiery-Vuillemin, A; Saad, F; Armstrong, AJ; Oya, M; Vianna, KCM; Ozguroglu, M; Gedye, C; Buchschacher, GL; Lee, JY; Emmenegger, U; Navratil, J ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
2022

Duke Scholars

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

2022

Volume

40

Issue

16

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Thiery-Vuillemin, A., Saad, F., Armstrong, A. J., Oya, M., Vianna, K. C. M., Ozguroglu, M., … Clarke, N. W. (2022). Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).
Thiery-Vuillemin, Antoine, Fred Saad, Andrew J. Armstrong, Mototsugu Oya, Karina Costa Maia Vianna, Mustafa Ozguroglu, Craig Gedye, et al. “Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.
Thiery-Vuillemin A, Saad F, Armstrong AJ, Oya M, Vianna KCM, Ozguroglu M, Gedye C, Buchschacher GL, Lee JY, Emmenegger U, Navratil J, Virizuela JA, Salazar A, Maillet D, Uemura H, Kim J, Lukacs E, Barker L, Degboe AN, Clarke NW. Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial. JOURNAL OF CLINICAL ONCOLOGY. 2022.

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

2022

Volume

40

Issue

16

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences